Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia

被引：0
|
作者：
John Lauriello
Peter J. Weiden
Carole D. Gleeson
Ankit Shah
Luke Boulanger
Krutika Jariwala-Parikh
Elizabeth Hedgeman
Amy K. O’Sullivan
机构：
[1] Jefferson Health—Sidney Kimmel Medical College,Department of Psychiatry and Human Behavior
[2] Thomas Jefferson University,undefined
[3] Alkermes,undefined
[4] IBM Watson Health,undefined
来源：
CNS Drugs | 2021年 / 35卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1123 / 1135
页数：12
相关论文
共 50 条
  • [41] Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting
    Di Lorenzo, Rosaria
    Ferri, Paola
    Cameli, Michela
    Rovesti, Sergio
    Piemonte, Chiara
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2019, 15 : 183 - 198
  • [42] Long-Acting Injectable Risperidone in the Treatment of Schizophrenia in Special Patient Populations
    Parellada, Eduard
    PSYCHOPHARMACOLOGY BULLETIN, 2007, 40 (02) : 82 - 100
  • [43] Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention
    Agid, Ofer
    Foussias, George
    Remington, Gary
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (14) : 2301 - 2317
  • [44] Comparisons of the effects of long-acting injectable monotherapy and combination therapy of long-acting injectable treatment with oral antipsychotics on treatment retention in patients with chronic schizophrenia
    Suzuki, Hidenobu
    Hibino, Hiroyuki
    Inoue, Yuichi
    Takaya, Atsuhiko
    ASIAN JOURNAL OF PSYCHIATRY, 2019, 39 : 112 - 113
  • [45] Adherence Challenges and Long-Acting Injectable Antipsychotic Treatment in Patients with Schizophrenia
    Morton, N. Kirk
    Zubek, Donna
    JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES, 2013, 51 (03) : 13 - 18
  • [46] Persistent Barriers to the Use of Long-Acting Injectable Antipsychotics for the Treatment of Schizophrenia
    Lindenmayer, Jean-Pierre
    Glick, Ira D.
    Talreja, Hiteshkumar
    Underriner, Michael
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2020, 40 (04) : 346 - 349
  • [47] Practical Guidance for the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia
    Riboldi, Ilaria
    Cavaleri, Daniele
    Capogrosso, Chiara A.
    Crocamo, Cristina
    Bartoli, Francesco
    Carra, Giuseppe
    PSYCHOLOGY RESEARCH AND BEHAVIOR MANAGEMENT, 2022, 15 : 3915 - 3929
  • [48] Efficacy, safety and tolerability of long-acting injectable aripiprazole (LAI-Ari) for long-term maintenance treatment in schizophrenia: 12-month prospective cohort study
    Stoimenova, M.
    Chumpalova, P.
    Todorov, A.
    Tumbev, L.
    Kolarov, P.
    Georgiev, G.
    Stoichev, K.
    Veleva, I.
    Popov, P.
    Kirov, K.
    Kozhuharov, H.
    Tonev, R.
    Valtchev, V.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 : S561 - S562
  • [49] Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia
    Turncliff, Ryan
    Hard, Marjie
    Du, Yangchun
    Risinger, Robert
    Ehrich, Elliot W.
    SCHIZOPHRENIA RESEARCH, 2014, 159 (2-3) : 404 - 410
  • [50] REAL-WORLD COSTS AND BUDGET IMPACT OF LONG-ACTING INJECTION ATYPICAL ANTIPSYCHOTICS FOR THE MANAGEMENT OF SCHIZOPHRENIA IN FRANCE
    Ortiz, I
    Clergeot, V
    Schmidt, R.
    VALUE IN HEALTH, 2018, 21 : S279 - S279
12345